BRCA2 and cervical clear cell adenocarcinoma: In this patient with a distant recurrence of clear cell cervical adenocarcinoma with a somatic BRCA2 mutation, treatment with single-agent olaparib resulted in a durable response of 14 months with limited toxicity.